Synthesis and primary evaluation of quinoxalinone derivatives as potent modulators of multidrug resistance

Medicinal Chemistry Research

Volumn 18, Issue 8, 2009, Pages 671-682

  Yuan, Hongyu ^a   Li, Xun ^a   Qu, Xianjun ^a   Sun, Lirui ^a   Xu, Wenfang ^a   Tang, Wei ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Multidrug resistance (MDR); P glycoprotein inhibitor; Quinoxalinone derivatives

Indexed keywords

2 [3 METHYL 2 OXOQUINOXALIN 1 (2H) YL] N 2 TOLYLACETAMIDE; 2 [3 METHYL 2 OXOQUINOXALIN 1 (2H) YL] N 4 TOLYLACETAMIDE; 2 [3 METHYL 2 OXOQUINOXALIN 1 (2H) YL] N PHENYLACETAMIDE; 2 [6,7 DIFLUORO 3 METHYL 2 OXOQUINOXALIN 1 (2H) N PHENYLACETAMIDE; 2 [6,7 DIMETHOXY 3 METHYL 2 OXOQUINOXALIN 1 (2H) N PHENYLACETAMIDE; DIETHYL 2 [2 (3 METHYL 2 OXOQUINAXOLIN 1 (2H) YL)ACETAMIDO]PENTANEDIOATE; DOXORUBICIN; ETHYL 2 [2 (3 METHYL 2 OXOQUINAXOLIN 1 (2H) YL)ACETAMIDO]ACETATE; ETHYL 2 [3 METHYL 2 OXOQUINOXALIN 1 (2H) YL]ACETATE; GLYCOPROTEIN P INHIBITOR; METHYL 2 [2 (3 METHYL 2 OXOQUINAXOLIN 1 (2H) YL)ACETAMIDO] 3 PHENYLPROPANOATE; METHYL 2 [2 (6,7 DIFLUORO 3 METHYL 2 OXOQUINAXOLIN 1 (2H) YL)ACETAMIDO] 3 PHENYLPROPANOATE; METHYL 2 [2 (6,7 DIMETHOXY 3 METHYL 2 OXOQUINAXOLIN 1 (2H) YL)ACETAMIDO] 3 PHENYLPROPANOATE; METHYL 4 HYDROXY 1 [2 (3 METHYL 2 OXOQUINOXALIN 1 (2H) YL)ACETYL]PYRROLIDINE 2 CARBOXYLATE; N (3 CHLORO 4 FLUOROPHENYL) 2 [3 METHYL 2 OXOQUINOXALIN 1 (2H) YL]ACETAMIDE; N (3,4 DICHLOROPHENYL) 2 [3 METHYL 2 OXOQUINOXALIN 1 (2H) YL]ACETAMIDE; N (3,4 DIFLUOROPHENYL) 2 [3 METHYL 2 OXOQUINOXALIN 1 (2H) YL]ACETAMIDE; N (3,4 DIMETHOXYPHENYL) 2 [3 METHYL 2 OXOQUINOXALIN 1 (2H) YL]ACETAMIDE; N (4 BROMOPHENYL) 2 [3 METHYL 2 OXOQUINOXALIN 1 (2H) YL]ACETAMIDE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BIOASSAY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE;

EID: 70449533147     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-008-9159-3     Document Type: Article

References (15)

1. MM Ali MMF Ismail MSA El-Gaby MA Zahran YA Ammar 2000 Synthesis and antimicrobial activities of some novel quinoxalinone derivatives Molecules 5 864 873 10.3390/50600864 10.3390/50600864 1:CAS:528:DC%2BD3cXlt1OrsLk%3D
2. RB Baudy LP Greenblatt IL Jirkovsky M Conklin RJ Russo DR Bramlett TA Emrey JT Simmonds DM Kowal RP Stein 1993 Potent quinoxaline-spaced phosphono alpha-amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation J Med Chem 36 331 342 10.1021/jm00055a004 10.1021/jm00055a004 1:CAS:528:DyaK3sXkt1ymtrc%3D 8093907
3. C Dell'erba B Chiavarina C Fenoglio G Petrillo C Cordazzo E Boncompagni D Spinelli E Ognio C Aiello MA Mariggio M Viale 2005 Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2, 3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo Pharmacol Res 52 271 282 10.1016/j.phrs.2005. 03.011 10.1016/j.phrs.2005.03.011 15921920 (Pubitemid 40981929)
4. M Hennessy JP Spiers 2007 A primer on the mechanics of P-glycoprotein the multidrug transporter Pharmacol Res 55 1 15 10.1016/j.phrs.2006.10.007 10.1016/j.phrs.2006.10.007 1:CAS:528:DC%2BD2sXntlequg%3D%3D 17095241 (Pubitemid 46108588)
5. S Jain S Laphookhieo Z Shi LW Fu S Akiyama ZS Chen DT Youssef RW van Soest KA El Sayed 2007 Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids J Nat Prod 70 928 931 10.1021/np0605889 10.1021/np0605889 1:CAS:528:DC%2BD2sXltVajt7w%3D 17488128 (Pubitemid 47056104)
6. FH Labeed HM Coley H Thomas MP Hughes 2003 Assessment of multidrug resistance reversal using dielectrophoresis and flow cytometry Biophys J 85 2028 2034 10.1016/S0006-3495(03)74630-X 1:CAS:528:DC%2BD3sXntFelsrY%3D 12944315
7. DS Lawrence JE Copper CD Smith 2001 Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists J Med Chem 44 594 601 10.1021/jm000282d 10.1021/jm000282d 1:CAS:528:DC%2BD3cXovFOjurw%3D 11170649 (Pubitemid 32162125)
8. Y Leblanc N Boudreault 1995 Para-directed amination of electron-rich arenes with bis(2,2,2-trichloroethyl) azodicarboxylate J Org Chem 60 4268 4271 10.1021/jo00118a052 1:CAS:528:DyaK2MXmt12rsLw%3D
9. X Li D Wang J Wu W Xu 2005 Novel approach to 3-methyl-1H-quinoxalin-2- ones Synth Commun 35 2553 2560 10.1080/00397910500213880 10.1080/ 00397910500213880 1:CAS:528:DC%2BD2MXhtVSks7jI (Pubitemid 41407684)
10. CA McDevitt R Callaghan 2007 How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 113 429 441 10.1016/j.pharmthera.2006.10.003 10.1016/j.pharmthera.2006.10.003 1:CAS:528:DC%2BD2sXhtVCgtbY%3D 17208306 (Pubitemid 46149055)
11. J Qi N Liu Y Zhou Y Tan Y Cheng C Yang Z Zhu D Xiong 2006 Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis Biochem Biophys Res Commun 349 303 309 10.1016/j.bbrc.2006.08. 042 10.1016/j.bbrc.2006.08.042 1:CAS:528:DC%2BD28XpsVKrtbg%3D 16934756 (Pubitemid 44348892)
12. XJ Qu JL Yang PJ Russell D Goldstein 2004 Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment J Urol 172 733 738 10.1097/01.ju.0000130751.83953.55 10.1097/01.ju.0000130751.83953.55 1:CAS:528:DC%2BD2cXlsFelsbo%3D 15247772 (Pubitemid 38900251)
13. J Robert C Jarry 2003 Multidrug resistance reversal agents J Med Chem 46 4805 4817 10.1021/jm030183a 10.1021/jm030183a 1:CAS:528:DC%2BD3sXnvFOisb8%3D 14584929
14. H Thomas F Frcr HM Coley 2003 Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer Control 10 159 165 12712010
15. K Yusa T Tsuruo 1989 Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells Cancer Res 49 5002 5006 1:CAS:528:DyaL1MXls1KqsL0%3D 2569930